Pfizer胜过Q2收入估计数,提高了2025年的前景,保持了红利。 Pfizer beats Q2 earnings estimates, raises 2025 outlook, maintains dividend.

Pfizer报告说,2025年第二季度收入强劲,收入为7.8 EPS和146.5亿美元,比全年的估计数高出10.3%。 Pfizer reported strong second-quarter 2025 earnings, with $0.78 EPS and $14.65 billion in revenue, surpassing estimates by 10.3% year-over-year. 该公司将其2025年EPS指南提高到2.90至3.10美元,同时保持季度股息0.43美元,收益率为7.0%。 The company raised its 2025 EPS guidance to $2.90–$3.10, while maintaining a $0.43 quarterly dividend yielding 7.0%. 包括Stratos财富伙伴和先锋在内的机构投资者持有重大利害关系,曼彻斯特金融公司减少了其地位。 Institutional investors, including Stratos Wealth Partners and Vanguard, held significant stakes, with Manchester Financial reducing its position. 股票交易额为24.52美元,市场上限为1 393.8亿美元,并有一致的“稳住”评级。 The stock trades at $24.52 with a market cap of $139.38 billion and a consensus "Hold" rating.